About

Welcome to the Lupus Forum. The Lupus Forum is an educational website developed under the auspices of the University of Leeds and is dedicated to the dissemination of the latest developments in the field of lupus. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of lupus, its treatments, and clinical practice.

Lupus Forum content is free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.

Membership of the Lupus Forum is free to everyone. Register as a member and have unlimited free access to all of the materials contained within the site.

View our ACR 2024 resources
Lupus Europe, now available on the useful links page
CLE Webinar

NEW Monthly literature search podcasts – available now

Steering Committee member Professor Victoria Werth, who is Chief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital, Pennsylvania, USA, is joined by fellow member Professor Chi-Chiu Mok, who is Chief of the Division of Rheumatology, Department of Medicine, Tuen Mun Hospital, Hong Kong, on the latest Lupus Forum podcast. Together, they discuss the efficacy and safety of iberdomide in CLE, as well as the efficacy and safety of SGLT2i vs. DPP4i for the primary prevention of cardiovascular disease and renal events in SLE and comorbid type 2 diabetes.

Latest Updates

Publications ▼
All
Publication thumbnail: Efficacy and safety of sodium-glucose co-transporter 2 inhibitors for the primary prevention of cardiovascular, renal events and safety outcomes in patients with systemic lupus erythematosus and comorbid type 2 diabetes: A population-based target trial emulation

Efficacy and safety of sodium-glucose co-transporter 2 inhibitors for the primary prevention of cardiovascular, renal events and safety outcomes in patients with systemic lupus erythematosus and comorbid type 2 diabetes: A population-based target trial emulation

Publication thumbnail: Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: a randomized phase 2 clinical trial

Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: a randomized phase 2 clinical trial

Publication thumbnail: Attainment of EULAR/ERA-EDTA targets of therapy with current immunosuppressive regimens and adjustments in treatment: a multicentre, real-life observational study

Attainment of EULAR/ERA-EDTA targets of therapy with current immunosuppressive regimens and adjustments in treatment: a multicentre, real-life observational study

Publication thumbnail: Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first-in-patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus

Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first-in-patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus

Steering Committee